{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:29:26Z","timestamp":1791916166468,"version":"4.3.4"},"reference-count":89,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.prp.2023.154732","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T21:07:18Z","timestamp":1690837638000},"page":"154732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Cancer immunotherapy focusing on the role of interleukins: A comprehensive and updated study"],"prefix":"10.1016","volume":"249","author":[{"given":"Mahmoud","family":"Samadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Kamrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Nasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Shomali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad Ahmadian","family":"Heris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parviz","family":"Shahabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazem","family":"Ghahremanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mohammadinasab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahram","family":"Sadeghvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak Sandoghchian","family":"Shotorbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7333-1300","authenticated-orcid":false,"given":"Morteza","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2023.154732_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fendo.2020.00280","article-title":"Cardiomyocyte senescence and cellular communications within myocardial microenvironments","volume":"11","author":"Tang","year":"2020","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.prp.2023.154732_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202300016","article-title":"Hiltonol, a dsRNA Mimic, promotes NK cell anti\u2010cancer cytotoxicity through TAZ cytoplasmic sequestration","author":"Wong","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.prp.2023.154732_bib3","doi-asserted-by":"crossref","first-page":"616","DOI":"10.3390\/ani9090616","article-title":"Anti-inflammatory state in Arabian horses introduced to the endurance training","volume":"9","author":"Witkowska-Pi\u0142aszewicz","year":"2019","journal-title":"Animals"},{"key":"10.1016\/j.prp.2023.154732_bib4","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000505099","article-title":"Interleukin-6: a masterplayer in the cytokine network","volume":"98","author":"Uciechowski","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.prp.2023.154732_bib5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/s12276-021-00649-0","article-title":"Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms","volume":"53","author":"Kang","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.prp.2023.154732_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108377","article-title":"Immune-related adverse events of checkpoint inhibitors: insights into immunological dysregulation","volume":"213","author":"Yang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.prp.2023.154732_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113928","article-title":"New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers","volume":"175","author":"Chyuan","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.prp.2023.154732_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108264","article-title":"Topoisomerase 2 inhibitor etoposide promotes interleukin-10 production in LPS-induced macrophages via upregulating transcription factor Maf and activating PI3K\/Akt pathway","volume":"101","author":"Zhang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.prp.2023.154732_bib9","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1002\/cam4.4060","article-title":"Interleukin\u201025: New perspective and state\u2010of\u2010the\u2010art in cancer prognosis and treatment approaches","volume":"10","author":"Gowhari Shabgah","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.prp.2023.154732_bib10","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.3324\/haematol.2020.271957","article-title":"MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma","volume":"106","author":"Ramis-Zaldivar","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.prp.2023.154732_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01198-9","article-title":"Dysregulated tumor-associated macrophages in carcinogenesis, progression and targeted therapy of gynecological and breast cancers","volume":"14","author":"Xu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.prp.2023.154732_bib12","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2023.154732_bib13","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.7150\/ijbs.46651","article-title":"The role of interleukins in colorectal cancer","volume":"16","author":"Li","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.prp.2023.154732_bib14","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prp.2023.154732_bib15","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jsbmb.2019.03.002","article-title":"Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression","volume":"189","author":"Bhardwaj","year":"2019","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.prp.2023.154732_bib16","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.3390\/ijms21103457","article-title":"Two-faced roles of tumor-associated neutrophils in cancer development and progression","volume":"21","author":"Mukaida","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154732_bib17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s13167-019-00194-x","article-title":"Chronic inflammation: key player and biomarker-set to predict and prevent cancer development and progression based on individualized patient profiles","volume":"10","author":"Qian","year":"2019","journal-title":"Epma J."},{"key":"10.1016\/j.prp.2023.154732_bib18","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.3389\/fimmu.2020.01444","article-title":"NLRP3 inflammasome activation in cancer: a double-edged sword","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154732_bib19","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.200111","article-title":"Mechanisms of immune suppression by myeloid-derived suppressor cells: the role of interleukin-10 as a key immunoregulatory cytokine","volume":"10","author":"Yaseen","year":"2020","journal-title":"Open Biol."},{"key":"10.1016\/j.prp.2023.154732_bib20","article-title":"Biology and therapeutic potential of interleukin-10","volume":"217","author":"Saraiva","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prp.2023.154732_bib21","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.coi.2008.03.010","article-title":"Role of Stat3 in suppressing anti-tumor immunity","volume":"20","author":"Kortylewski","year":"2008","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.prp.2023.154732_bib22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3390\/vaccines4030022","article-title":"The IL-8\/IL-8R axis: a double agent in tumor immune resistance","volume":"4","author":"David","year":"2016","journal-title":"Vaccines"},{"key":"10.1016\/j.prp.2023.154732_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007965","article-title":"Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model","volume":"4","author":"Liao","year":"2009","journal-title":"PloS One"},{"key":"10.1016\/j.prp.2023.154732_bib24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.omto.2023.01.001","article-title":"Breast cancer tumor microenvironment affects Treg\/IL-17-producing Treg\/Th17 cell axis: molecular and therapeutic perspectives","volume":"28","author":"Seif","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.prp.2023.154732_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12863","article-title":"IL2RG\u2010deficient minipigs generated via CRISPR\/Cas9 technology support the growth of human melanoma\u2010derived tumours","volume":"53","author":"Ren","year":"2020","journal-title":"Cell Prolif."},{"key":"10.1016\/j.prp.2023.154732_bib26","article-title":"767 Safety and preliminary efficacy of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L\/IL-23\/IL-36\u03b3 for intratumoral (ITu) injection, and durvalumab (IV) in TNBC, HNSCC, and melanoma","author":"Olson","year":"2022","journal-title":"BMJ Spec. J."},{"key":"10.1016\/j.prp.2023.154732_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104254","article-title":"IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy","volume":"359","author":"Weber","year":"2021","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.prp.2023.154732_bib28","first-page":"8","article-title":"ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy","author":"Lopes","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2023.154732_bib29","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.3390\/cancers12123586","article-title":"Immunomodulatory effects of IL-2 and IL-15; implications for cancer immunotherapy","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154732_bib30","article-title":"722 INBRX-121 is an NKp46-targeted detuned IL-2 with antitumor activity as a monotherapy or in combination with multiple cancer immunotherapy modalities","author":"Sulzmaier","year":"2021","journal-title":"BMJ Spec. J."},{"key":"10.1016\/j.prp.2023.154732_bib31","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","article-title":"Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy","volume":"14","author":"Bhatia","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.prp.2023.154732_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2023.154732_bib33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3390\/cancers12010130","article-title":"In the absence of a TCR Signal IL-2\/IL-12\/18-stimulated \u03b3\u03b4 T cells demonstrate potent anti-tumoral function through direct killing and senescence induction in cancer cells","volume":"12","author":"Schilbach","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154732_bib34","doi-asserted-by":"crossref","first-page":"45873","DOI":"10.1021\/acsami.0c14405","article-title":"Tumor microenvironment-triggered charge reversal polymetformin-based nanosystem co-delivered doxorubicin and IL-12 cytokine gene for chemo\u2013gene combination therapy on metastatic breast cancer","volume":"12","author":"Sun","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.prp.2023.154732_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104042","article-title":"Dual-target IL-12-containing nanoparticles enhance T cell functions for cancer immunotherapy","volume":"349","author":"Li","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.prp.2023.154732_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.it.2022.08.004","article-title":"Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy","author":"Ma","year":"2022","journal-title":"Trends Immunol."},{"issue":"112","key":"10.1016\/j.prp.2023.154732_bib37","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/JLB.5MR0422-506R","article-title":"update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy","volume":"2022","author":"Peng","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.prp.2023.154732_bib38","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/cancers13040837","article-title":"Heterodimeric IL-15 in cancer immunotherapy","volume":"13","author":"Bergamaschi","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154732_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.614667","article-title":"IL-15\/IL-15R\u03b1 heterodimeric complex as cancer immunotherapy in murine breast cancer models","volume":"11","author":"Guo","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154732_bib40","first-page":"217","article-title":"Interleukin-15 (dys) regulation of lymphoid homeostasis: implications for therapy of autoimmunity and cancer","author":"Waldmann","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prp.2023.154732_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.prp.2023.154732_bib42","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.prp.2023.154732_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107692","article-title":"Interleukin-8: a chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppression","volume":"219","author":"Fousek","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.prp.2023.154732_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0522-3","article-title":"Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition","volume":"7","author":"Buchbinder","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2023.154732_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.prp.2023.154732_bib46","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.21873\/anticanres.15110","article-title":"Cytokine-based cancer immunotherapy: challenges and opportunities for IL-10","volume":"41","author":"Rallis","year":"2021","journal-title":"Anticancer Res."},{"key":"10.1016\/j.prp.2023.154732_bib47","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cam4.4659","article-title":"Checkpoint inhibitor\/interleukin\u2010based combination therapy of cancer","volume":"11","author":"Mortezaee","year":"2022","journal-title":"Cancer Med."},{"key":"10.1016\/j.prp.2023.154732_bib48","first-page":"11","article-title":"Interleukin-based treatments find footing in ongoing research","author":"Holmes","year":"2022","journal-title":"Target. Ther. Oncol."},{"key":"10.1016\/j.prp.2023.154732_bib49","doi-asserted-by":"crossref","first-page":"4369","DOI":"10.1007\/s00259-021-05407-y","article-title":"Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy","volume":"48","author":"van de Donk","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.prp.2023.154732_bib50","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00262-022-03144-1","article-title":"Interleukin-12 as an in situ cancer vaccine component: a review","volume":"71","author":"Cheng","year":"2022","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.prp.2023.154732_bib51","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.3390\/cancers14225592","article-title":"Antitumor activities of interleukin-12 in melanoma","volume":"14","author":"Gao","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154732_bib52","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.3390\/cells12121611","article-title":"Exploiting an interleukin-15 heterodimeric agonist (N803) for effective immunotherapy of solid malignancies","volume":"12","author":"Lui","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.prp.2023.154732_bib53","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/17425247.2020.1764933","article-title":"Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges","volume":"17","author":"Tan","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.prp.2023.154732_bib54","first-page":"22","article-title":"Therapeutic potential of interleukin-15 in cancer","author":"Surcel","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.prp.2023.154732_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1141208","article-title":"The role of interleukin-15 in the development and treatment of hematological malignancies","volume":"14","author":"Sindaco","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2023.154732_bib56","first-page":"21","article-title":"Roles of IL-1 in cancer: from tumor progression to resistance to targeted therapies","author":"Gelfo","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.prp.2023.154732_bib57","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.3390\/nu14163299","article-title":"Anti-colorectal cancer effects of inonotus hispidus (Bull.: Fr.) p. karst. spore powder through regulation of gut microbiota-mediated JAK\/STAT signaling","volume":"14","author":"Yang","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.prp.2023.154732_bib58","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.3889\/oamjms.2019.589","article-title":"IL-6 activities in the tumour microenvironment. Part 1","volume":"7","author":"Chonov","year":"2019","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"10.1016\/j.prp.2023.154732_bib59","first-page":"1971","article-title":"JAK-STAT signalling pathway in cancer","author":"Brooks","year":"2020","journal-title":"MDPI"},{"key":"10.1016\/j.prp.2023.154732_bib60","article-title":"1087 Addition of IL-2 overcomes lung tumor resistance to IL-12 by coordinating cytotoxic and regulatory T cell responses","author":"Horton","year":"2022","journal-title":"BMJ Spec. J."},{"key":"10.1016\/j.prp.2023.154732_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4544773","article-title":"IL-2 combined with IL-15 enhanced the expression of NKG2D receptor on patient autologous NK cells to inhibit wilms\u2019 tumor via MAPK signaling pathway","volume":"2022","author":"Li","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.prp.2023.154732_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120218","article-title":"Protective role of irbesartan against cyclophosphamide-induced testicular damage in rats via up-regulating PPAR-\u03b3 signaling and ameliorating NF-\u03baB\/NLRP3\/IL-18 inflammatory axis","volume":"289","author":"Abu-Risha","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.prp.2023.154732_bib63","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00262-020-02751-0","article-title":"Low-dose ipilimumab plus nivolumab combined with IL-2 and hyperthermia in cancer patients with advanced disease: exploratory findings of a case series of 131 stage IV cancers\u2013a retrospective study of a single institution","volume":"70","author":"Kleef","year":"2021","journal-title":"Cancer Immunol., Immunother."},{"key":"10.1016\/j.prp.2023.154732_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.prp.2023.154732_bib65","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","article-title":"CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients","volume":"19","author":"Ott","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154732_bib66","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10787-022-00933-z","article-title":"Immune-related adverse events (irAEs) in ankylosing spondylitis (AS) patients treated with interleukin (IL)-17 inhibitors: a systematic review and meta-analysis","volume":"30","author":"Azadeh","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.prp.2023.154732_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-6138-7","article-title":"Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports","volume":"19","author":"Yoshino","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2023.154732_bib68","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1080\/17460441.2020.1795124","article-title":"Preclinical discovery and clinical development of encorafenib for the treatment of melanoma","volume":"15","author":"Okten","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.prp.2023.154732_bib69","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3390\/pathogens10060694","article-title":"Synergistic activation of bovine CD4+ T cells by neutrophils and IL-12","volume":"10","author":"Xiao","year":"2021","journal-title":"Pathogens"},{"key":"10.1016\/j.prp.2023.154732_bib70","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.3390\/cancers14184512","article-title":"Therapeutic adenovirus vaccine combined immunization with IL-12 induces potent CD8+ T cell anti-tumor immunity in hepatocellular carcinoma","volume":"14","author":"Zheng","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2023.154732_bib71","first-page":"7","article-title":"Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?","author":"Zibelman","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.prp.2023.154732_bib72","first-page":"118","article-title":"Effect of interleukin-2 combined with interferon alpha on immune function of patients with liver cancer after operation","author":"Shang","year":"2021","journal-title":"Ind. J. Pharm. Sci."},{"key":"10.1016\/j.prp.2023.154732_bib73","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201847575","article-title":"The emerging roles of inflammasome\u2010dependent cytokines in cancer development","volume":"20","author":"Van Gorp","year":"2019","journal-title":"EMBO Rep."},{"key":"10.1016\/j.prp.2023.154732_bib74","first-page":"217","article-title":"Emerging roles of IL-34 in health and disease","author":"Lelios","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.prp.2023.154732_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.omto.2023.01.001","article-title":"The impact of tumor microenvironment secretome on Treg\/IL-17\u2013producing Treg\/Th17 cells axis in breast cancer: molecular and therapeutic perspectives","author":"Seif","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.prp.2023.154732_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115536","article-title":"Expressing IL-15\/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer","volume":"212","author":"Ruixin","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.prp.2023.154732_bib77","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1073\/pnas.1814642116","article-title":"IL-15 is a component of the inflammatory milieu in the tumor microenvironment promoting antitumor responses","volume":"116","author":"Santana Carrero","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.prp.2023.154732_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-019-1310-0","article-title":"IL-6 and IL-8 secreted by tumour cells impair the function of NK cells via the STAT3 pathway in oesophageal squamous cell carcinoma","volume":"38","author":"Wu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.prp.2023.154732_bib79","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s13402-022-00667-8","article-title":"Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy","volume":"45","author":"Mortezaee","year":"2022","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.prp.2023.154732_bib80","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.canlet.2021.06.009","article-title":"Cancer-associated fibroblasts induce monocytic myeloid-derived suppressor cell generation via IL-6\/exosomal miR-21-activated STAT3 signaling to promote cisplatin resistance in esophageal squamous cell carcinoma","volume":"518","author":"Zhao","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2023.154732_bib81","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/vaccines11061033","article-title":"Electrochemotherapy plus IL-2+ IL-12 gene electrotransfer in spontaneous inoperable stage III\u2013IV canine oral malignant melanoma","volume":"11","author":"Tellado","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.prp.2023.154732_bib82","doi-asserted-by":"crossref","first-page":"7039","DOI":"10.1007\/s00253-022-12209-1","article-title":"A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities","volume":"106","author":"Lv","year":"2022","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"10.1016\/j.prp.2023.154732_bib83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/eji.201343509","article-title":"CD 161++ CD 8+ T cells, including the MAIT cell subset, are specifically activated by IL\u201012+ IL\u201018 in a TCR\u2010independent manner","volume":"44","author":"Ussher","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.prp.2023.154732_bib84","article-title":"IL-18 modulates excitation contraction coupling in human airway smooth muscle cells","author":"Woo","year":"2022","journal-title":"B60 Asthma Allergic Responses: Cells, Tissues, Anim. Models: Am. Thorac. Soc."},{"key":"10.1016\/j.prp.2023.154732_bib85","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jconrel.2020.09.040","article-title":"Dual-adjuvant effect of pH-sensitive liposomes loaded with STING and TLR9 agonists regress tumor development by enhancing Th1 immune response","volume":"328","author":"Kocabas","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2023.154732_bib86","first-page":"9","article-title":"Current status of intralesional agents in treatment of malignant melanoma","author":"Zawit","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.prp.2023.154732_bib87","article-title":"A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy","author":"Dower","year":"2023","journal-title":"bioRxiv"},{"key":"10.1016\/j.prp.2023.154732_bib88","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40259-020-00451-w","article-title":"Clinical trials of IL-12\/IL-23 inhibitors in inflammatory bowel disease","volume":"34","author":"Almradi","year":"2020","journal-title":"BioDrugs"},{"key":"10.1016\/j.prp.2023.154732_bib89","first-page":"2019","author":"Bai","year":"2019","journal-title":"J. Immunol. Res."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823004326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823004326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T07:01:20Z","timestamp":1759734080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823004326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":89,"alternative-id":["S0344033823004326"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154732","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer immunotherapy focusing on the role of interleukins: A comprehensive and updated study","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"154732"}}